{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:39:08Z","timestamp":1787031548585,"version":"build-2736575974"},"reference-count":61,"publisher":"Rambam Health Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"DOI":"10.5041\/rmmj.10333","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T10:20:43Z","timestamp":1524219643000},"page":"e0013","source":"Crossref","is-referenced-by-count":30,"title":["Porphyria: What Is It and Who Should Be Evaluated?"],"prefix":"10.5041","volume":"9","author":[{"given":"Yonatan","family":"Edel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rivka","family":"Mamet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jemermed.2015.04.034","article-title":"Acute porphyrias","volume":"49","author":"Besur","year":"2015","unstructured":"1. Besur S, Schmeltzer P, Bonkovsky HL. Acute porphyrias. J Emerg Med 2015;49:305-12.","journal-title":"J Emerg Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Porphyria","volume":"377","author":"Bissell","year":"2017","unstructured":"2. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med 2017;377:862-72.","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.clinre.2015.05.009","article-title":"Porphyrias: a 2015 update","volume":"39","author":"Karim","year":"2015","unstructured":"3. Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: a 2015 update. Clin Res Hepatol Gastroenterol 2015;39:412-25.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.amjmed.2014.10.026","article-title":"Role of delta-aminolevulinic acid in the symptoms of acute porphyria","volume":"128","author":"Bissell","year":"2015","unstructured":"4. Bissell DM, Lai JC, Meister RK, Blanc PD. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med 2015;128:313-17.","journal-title":"Am J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/s-2007-1007139","article-title":"Acute porphyrias: pathogenesis of neurological manifestations","volume":"18","author":"Meyer","year":"1998","unstructured":"5. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998;18:43-52.","journal-title":"Semin Liver Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.det.2014.03.001","article-title":"The cutaneous porphyrias","volume":"32","author":"Schulenburg-Brand","year":"2014","unstructured":"6. Schulenburg-Brand D, Katugampola R, Anstey AV, Badminton MN. The cutaneous porphyrias. Dermatol Clin 2014;32:369-84.","journal-title":"Dermatol Clin"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/0004563216667965","article-title":"Best practice guidelines on first-line laboratory testing for porphyria","volume":"54","author":"Woolf","year":"2017","unstructured":"7. Woolf J, Marsden JT, Degg T, et al. Best practice guidelines on first-line laboratory testing for porphyria. Ann Clin Biochem 2017;54:188-98.","journal-title":"Ann Clin Biochem"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/metabo4040977","article-title":"Clinically important features of porphyrin and heme metabolism and the porphyrias","volume":"4","author":"Besur","year":"2014","unstructured":"8. Besur S, Hou W, Schmeltzer P, Bonkovski HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites 2014;4: 977-1006.","journal-title":"Metabolites"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10545-005-8050-3","article-title":"Molecular mechanisms of dominant expression in porphyria","volume":"28","author":"MN","year":"2005","unstructured":"9. Badminton MN, Elder GH. Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 2005;28: 277-86.","journal-title":"J Inherit Metab Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bjh.14459","article-title":"Update review of the acute porphyrias","volume":"176","author":"Stein","year":"2017","unstructured":"10. Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol 2017;176:527-38.","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ajem.2004.03.013","article-title":"ED presentation of acute porphyria","volume":"23","author":"Liu","year":"2005","unstructured":"11. Liu YP, Lien WC, Fang CC, Lai TI, Chen WJ, Wang HP. ED presentation of acute porphyria. Am J Emerg Med 2005;23:164-7.","journal-title":"Am J Emerg Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-199201000-00001","article-title":"Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases","volume":"71","author":"Kauppinen","year":"1992","unstructured":"12. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992;71:1-13.","journal-title":"Medicine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/0002-9343(79)91176-8","article-title":"Relationship of the 5\u03b1-reductive metabolism of steroid hormones to clinical expression of the genetic defect in acute intermittent porphyria","volume":"66","author":"Anderson","year":"1979","unstructured":"13. Anderson KE, Bradlow HL, Sassa S, Kappas A. Studies in porphyria: VIII. Relationship of the 5\u03b1-reductive metabolism of steroid hormones to clinical expression of the genetic defect in acute intermittent porphyria. Am J Med 1979;66:644-50.","journal-title":"Am J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/alcalc\/35.2.109","article-title":"Alcohol and porphyrin metabolism","volume":"35","author":"Doss","year":"2000","unstructured":"14. Doss MO, Kuhnel A, Gross U. Alcohol and porphyrin metabolism. Alcohol Alcohol 2000;35:109-25.","journal-title":"Alcohol Alcohol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cell.2005.06.040","article-title":"Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1\u03b1","volume":"122","author":"Handschin","year":"2005","unstructured":"15. Handschin C, Jiandie L, Rhee J, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1\u03b1. Cell 2005;122:505-15.","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/280514a0","article-title":"Delta-aminolaevulinic acid is a potent agonist for GABA autoreceptors","volume":"280","author":"MJ","year":"1979","unstructured":"16. Bremmam MJ, Cantrill RC. Delta-aminolaevulinic acid is a potent agonist for GABA autoreceptors. Nature 1979;280:514-15.","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1011034409814","article-title":"5-Aminolevulinic acid inhibits [3H] muscimol binding to human and rat brain synaptic membranes","volume":"26","author":"Emanuelli","year":"2001","unstructured":"17. Emanuelli T, Pagel FW, Alves LB, Regner A, Souza DO. 5-Aminolevulinic acid inhibits [3H] muscimol binding to human and rat brain synaptic membranes. Neurochem Res 2001;26:101-5.","journal-title":"Neurochem Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/0024-3205(93)90271-4","article-title":"Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks","volume":"53","author":"Puy","year":"1993","unstructured":"18. Puy H, Deybach JC, Baudry P, Callebert J, Touitou Y, Nordmann Y. Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks. Life Sci 1993;53:621-7.","journal-title":"Life Sci"},{"key":"ref18","unstructured":"19. Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria (AIP). Cell Mol Biol (Noisy-le-grand) 2009;55:72-83."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.pediatrneurol.2014.05.016","article-title":"Posterior reversible encephalopathy syndrome in acute intermittent porphyria","volume":"51","author":"Zao","year":"2014","unstructured":"20. Zao B, Wei Q, Wang Y, Chen Y, Shang H. Posterior reversible encephalopathy syndrome in acute intermittent porphyria. Pediat Neurol 2014;51:457-60.","journal-title":"Pediat Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.psym.2012.03.008","article-title":"Acute Intermittent porphyria presenting solely with psychosis: a case report and discussion","volume":"53","author":"Kumar","year":"2012","unstructured":"21. Kumar B. Acute Intermittent porphyria presenting solely with psychosis: a case report and discussion. Psychosomatics 2012;53:494-8.","journal-title":"Psychosomatics"},{"key":"ref21","unstructured":"22. Ellencweig N, Schoenfeld N, Zemishlany Z. Acute intermittent porphyria: psychosis as the only clinical manifestation. Isr J Psychiatry Relat Sci 2006;43:52-6."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2141.2006.06289.x","article-title":"Modern diagnosis and management of the porphyrias","volume":"135","author":"Sassa","year":"2006","unstructured":"23. Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol 2006;135:281-92.","journal-title":"Br J Haematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","article-title":"The incidence of inherited porphyrias in Europe","volume":"36","author":"Elder","year":"2013","unstructured":"24. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis 2013;36:849-57.","journal-title":"J Inherit Metab Dis"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Anderson KE, Collins S. Open-label study of hemin for acute phorphyria: clinical practice. Am J Med 2006;119:801.e19-24.","DOI":"10.1016\/j.amjmed.2006.05.026"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/TACG.S48605","article-title":"An update of clinical management of acute intermittent porphyria","volume":"8","author":"Pischik","year":"2015","unstructured":"26. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. App Clin Genet 2015;8:201-14.","journal-title":"App Clin Genet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3109\/00016340903390729","article-title":"Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria","volume":"89","author":"Innala","year":"2010","unstructured":"27. Innala E, Backstrom T, Bixo M, Andersson C. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand 2010;89:95-100.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","article-title":"Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium","volume":"127","author":"Bonkovsky","year":"2014","unstructured":"28. Bonkovsky HL, Maddukuri VC, Yazici C, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med 2014;127:1233-41.","journal-title":"Am J Med"},{"key":"ref28","unstructured":"29. Church SE, McColl KE, Moore MR, Youngs GR. Hypertension and renal impairment as complications of acute porphyria. Nephrol Dial Transplant 1992;7: 986-90."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1046\/j.1365-2796.2000.00743.x","article-title":"Renal symptomatology in patients with acute intermittent porphyria: a population based study","volume":"248","author":"Andersson","year":"2000","unstructured":"30. Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria: a population based study. J Intern Med 2000;248:319-25.","journal-title":"J Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/ki.2015.97","article-title":"High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria","volume":"88","author":"Pallet","year":"2015","unstructured":"31. Pallet N, Mami L, Schmitt C, et al. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Int 2015;88:386-95.","journal-title":"Kidney Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1136\/jclinpath-2012-200791","article-title":"Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up","volume":"65","author":"Stewart","year":"2012","unstructured":"32. Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol 2012;65:976-80.","journal-title":"J Clin Pathol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/003655100300054891","article-title":"The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W: a population-based study","volume":"60","author":"Andersson","year":"2000","unstructured":"33. Andersson C, Floderus Y, Wikberg A, Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W: a population-based study. Scand J Clin Lab Invest 2000;60:643-8.","journal-title":"Scand J Clin Lab Invest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/humu.23067","article-title":"Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease","volume":"37","author":"Chen","year":"2016","unstructured":"34. Chen B, Solis-Villa C, Hakenberg J, et al. Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Hum Mutat 2016;37:1215-22.","journal-title":"Hum Mutat"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1046\/j.1365-2796.1997.00189.x","article-title":"Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France","volume":"242","author":"Nordmann","year":"1997","unstructured":"35. Nordmann Y, Puy H, Da Silva V, et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med 1997;242:213-17.","journal-title":"J Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1023\/B:BOLI.0000037341.21975.9d","article-title":"The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany","volume":"27","author":"Doss","year":"2004","unstructured":"36. Doss MO, Stauch T, Gross U, et al. The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis 2004;27:529-36.","journal-title":"J Inherit Metab Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1023\/B:BOLI.0000016613.75677.05","article-title":"Homozygous acute intermittent porphyria in a 7 year old boy with massive excretions of porphyrins and porphyrin precursors","volume":"27","author":"Hessels","year":"2004","unstructured":"37. Hessels J, Voortman G, van der Wagen A, van der Elzen C, Scheffer H, Zuijderhoudt FM. Homozygous acute intermittent porphyria in a 7 year old boy with massive excretions of porphyrins and porphyrin precursors. J Inherit Metab Dis 2004;27:19-27.","journal-title":"J Inherit Metab Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/hmg\/3.3.477","article-title":"Homozygous hereditary coproporphyria caused by an arginine to tryptophane substitution in coproporphyrinogen oxidase and common intragenic polymorphisms","volume":"3","author":"Martasek","year":"1994","unstructured":"38. Martasek P, Nordmann Y Grandchamp B. Homozygous hereditary coproporphyria caused by an arginine to tryptophane substitution in coproporphyrinogen oxidase and common intragenic polymorphisms. Hum Mol Genet 1994;3:477-80.","journal-title":"Hum Mol Genet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2133.2005.06978.x","article-title":"A Chilean boy with severe photosensitivity and finger shortening: the first case of homozygous porphyria in South America","volume":"154","author":"Poblete-Gutierrez","year":"2006","unstructured":"39. Poblete-Gutierrez P, Wolff C, Farias R, Frank J. A Chilean boy with severe photosensitivity and finger shortening: the first case of homozygous porphyria in South America. Br J Dermatol 2006;154:368-71.","journal-title":"Br J Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/oem.50.12.1119","article-title":"Plumboporphyria (ALAD deficiency) in a lead worker: a scenario for potential diagnostic confusion","volume":"50","author":"Dyer","year":"1993","unstructured":"40. Dyer J, Garnick DP, Inglis A, Pye IF. Plumboporphyria (ALAD deficiency) in a lead worker: a scenario for potential diagnostic confusion. Br J Ind Med 1993;50:1119-21.","journal-title":"Br J Ind Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/clinchem\/47.9.1710","article-title":"Lead poisoning: a new biochemical perspective on the differentiation between acquired and hereditary neuroporphyria","volume":"47","author":"Mamet","year":"2001","unstructured":"41. Mamet R, Sztern M, Rachmel A, Stahl B, Flusser D, Schoenfeld N. Lead poisoning: a new biochemical perspective on the differentiation between acquired and hereditary neuroporphyria. Clin Chem 2001; 47:1710-13.","journal-title":"Clin Chem"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/hep.510270627","article-title":"Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north America","volume":"27","author":"Bonkovsky","year":"1998","unstructured":"42. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north America. Hepatology 1998;27: 1661-9.","journal-title":"Hepatology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s12328-017-0772-x","article-title":"Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir\/sofosbuvir for hepatitis C","volume":"10","author":"Takata","year":"2017","unstructured":"43. Takata K, Shakado S, Sakamoto K, et al. Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir\/sofosbuvir for hepatitis C. Clin J Gastroenterol 2017;10:459-63.","journal-title":"Clin J Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14712\/fb2015061060219","article-title":"Hepatoerythropoietic porphyria caused by a novel homoallelic Mutation in Uroporphyrinogen decarboxylase gene in Egyptian patients","volume":"61","author":"Farrag","year":"2015","unstructured":"44. Farrag MS, Midula I, Richard E, Sauder V, De Verneuil H, Martasek P. Hepatoerythropoietic porphyria caused by a novel homoallelic Mutation in Uroporphyrinogen decarboxylase gene in Egyptian patients. Folia Biol (Praha) 2015;61:219-26.","journal-title":"Folia Biol (Praha)"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/0002-9343(76)90528-3","article-title":"10 years' experience","volume":"60","author":"DeLeo","year":"1976","unstructured":"45. DeLeo VA, Poh-Fitzpatrick M, Mathews-Roth M, Harber LC. Erythropoietic protoporphyria. 10 years' experience. Am J Med 1976;60:8-22.","journal-title":"Am J Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1182\/blood-2007-04-088120","article-title":"Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria","volume":"110","author":"Holme","year":"2007","unstructured":"46. Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007;110:4108-10.","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2119\/molmed.2012.00340","article-title":"Loss of function ferrochelatase and gain of function erythroid-specific 5-aminolevulinate synthase mutation causing erythropoietic protoporphyria and X-linked protoporphyria in North American patients reveal novel mutations and high prevalence of X-linked protoporphyria","volume":"19","author":"Balwani","year":"2013","unstructured":"47. Balwani M, Doheny D, Bishop D, et al. Loss of function ferrochelatase and gain of function erythroid-specific 5-aminolevulinate synthase mutation causing erythropoietic protoporphyria and X-linked protoporphyria in North American patients reveal novel mutations and high prevalence of X-linked protoporphyria. Mol Med 2013;19:26-35.","journal-title":"Mol Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cge.12562","article-title":"X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria","volume":"89","author":"Brancaleoni","year":"2016","unstructured":"48. Brancaleoni V, Balwani M, Granata F, et al. X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria. Clin Genet 2016;89:20-6.","journal-title":"Clin Genet"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ng809","article-title":"The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH","volume":"30","author":"Gouya","year":"2002","unstructured":"49. Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nature Genet 2002;30:27-8.","journal-title":"Nature Genet"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/498620","article-title":"Contribution of a common single nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria","volume":"78","author":"Gouya","year":"2006","unstructured":"50. Gouya L, Marine-Schmitt C, Robreau AM, et al. Contribution of a common single nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet 2006;78:2-14.","journal-title":"Am J Hum Genet"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51. Schneder-Yin X, Mamet R, Minder EI, Schoenfeld N. Biochemical and molecular diagnosis of erythropoietic protoporphyria in an Ashkenazi Jewish family. J Inherit Metab Dis 2008;31(Suppl 2):S363-7.","DOI":"10.1007\/s10545-008-0924-8"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/jid.2008.272","article-title":"Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance","volume":"129","author":"Holme","year":"2009","unstructured":"52. Holme SA, Whatley SD, Roberts AG, et al. Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Invest Dermatol 2009;129:599-605.","journal-title":"J Invest Dermatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/j.1468-3083.2010.03640.x","article-title":"A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma","volume":"24","author":"Minder","year":"2010","unstructured":"53. Minder EI, Schneider-Yin X, Mamet R, et al. A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma. J Eur Acad Dermatol Venerol 2010;24:1349-53.","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.12688\/f1000research.10101.1","article-title":"An overview of the cutaneous porphyrias","volume":"6","author":"Dawe","year":"2017","unstructured":"54. Dawe R. An overview of the cutaneous porphyrias. F1000Res 2017;6:1906.","journal-title":"F1000Res"},{"key":"ref54","unstructured":"55. Balwany M, Bloomer J, Desnick R, Balwani M, Bloomer J, Desnick R; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Erythropoietic Protoporphyria, Autosomal Recessive. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. SourceGeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. [Last update: September 7, 2017]."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2133.1977.tb14273.x","article-title":"The long-term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial","volume":"97","author":"Corbett","year":"1977","unstructured":"56. Corbett MF, Herxheimer, A, Magnus IA, Ramsay CA, Kobza-Black A. The long-term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 1977;97:655-62.","journal-title":"Br J Dermatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40262-016-0501-5","article-title":"Pharmacokinetics and pharmacodynamics of Afamelanotide and its clinical use in treatment dermatologic disorders","volume":"56","author":"Minder","year":"2017","unstructured":"57. Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of Afamelanotide and its clinical use in treatment dermatologic disorders. Clin Pharmacokinet 2017;56:815-23.","journal-title":"Clin Pharmacokinet"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1365-2133.2008.08616.x","article-title":"Serum 25-hydroxyvitamin D in erythropoietic protoporphyria","volume":"159","author":"Holme","year":"2008","unstructured":"58. Holme SA, Anstey AV, Badminton MN, Elder GH. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. Br J Dermatol 2008;159:211-13.","journal-title":"Br J Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"59. Spet JMC, de Rooij FWM, Wilson JHP, Zandbergen AAM. Vitamin D deficiency in patients with erythropoietic protoporphyria. J Inherit Metab Dis 2010;33 (Suppl 3):S1-4.","DOI":"10.1007\/s10545-008-1037-0"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/bjd.15893","article-title":"Osteoporosis in patients with erythropoietic protoporphyria","volume":"177","author":"Biewenga","year":"2017","unstructured":"60. Biewenga M, Matawile RHS, Friesema ECH, et al. Osteoporosis in patients with erythropoietic protoporphyria. Br J Dermatol 2017;177:1693-8.","journal-title":"Br J Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/pde.12117","article-title":"Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation","volume":"30","author":"Martinez Peinado","year":"2013","unstructured":"61. Martinez Peinado C, D\u00edaz de Heredia C, To-Figueras J, et al. Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation. Pediatr Dermatol 2013;30:484-9.","journal-title":"Pediatr Dermatol"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/803\/1\/PublishFiles\/818Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T12:10:14Z","timestamp":1754223014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/37\/articles\/818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,4,19]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10333","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]}}}